ketoconazole has been researched along with alfentanil in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dale, O; Kharasch, ED; Klees, TM; Sheffels, P | 1 |
| Blood, J; Buck, N; Kharasch, ED; Kim, T; London, A; Mach, RH; Vangveravong, S | 1 |
1 review(s) available for ketoconazole and alfentanil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for ketoconazole and alfentanil
| Article | Year |
|---|---|
Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.
Topics: Administration, Oral; Adult; Alfentanil; Anesthetics, Intravenous; Area Under Curve; Beverages; Citrus paradisi; Cross-Over Studies; Cytochrome P-450 CYP3A; Deuterium; Drug Administration Schedule; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Intestinal Mucosa; Ketoconazole; Liver; Male; Miosis; Rifampin; Young Adult | 2011 |
5 other study(ies) available for ketoconazole and alfentanil
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Topics: Alfentanil; Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochromes b5; Enzyme Inhibitors; Humans; In Vitro Techniques; Isoenzymes; Ketoconazole; Kinetics; Microsomes; Oxidoreductases, N-Demethylating; Troleandomycin | 2005 |